Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
02 Janvier 2024 - 1:00PM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing a new class of small molecule
medicines using targeted protein degradation (TPD), today announced
the Company will present at the 42nd Annual J.P. Morgan Healthcare
Conference in San Francisco, California on Tuesday, January 9,
2024, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, Ph.D.,
Founder, President and CEO, will provide an overview of the
Company’s progress and anticipated milestones for 2024.
A live webcast of the presentation and Q&A
session will be available under the "Events and Presentations"
section of the Investors page on the Company's website at
www.kymeratx.com. A replay of the webcast will be archived on
Kymera’s website and available for 30-days following the event.
About Kymera
Therapeutics Kymera is a clinical-stage biotechnology
company pioneering the field of targeted protein degradation (TPD)
to develop medicines that address critical health problems and have
the potential to dramatically improve patients’ lives. Kymera is
deploying TPD to address disease targets and pathways inaccessible
with conventional therapeutics. Having advanced the first degrader
into the clinic for immunological diseases, Kymera is focused on
delivering oral small molecule degraders to provide a new
generation of convenient, highly effective therapies for patients
with these conditions. Kymera is also progressing degrader oncology
programs that target undrugged or poorly drugged proteins to create
new ways to fight cancer. Founded in 2016, Kymera has been
recognized as one of Boston’s top workplaces. For more information
about our science, pipeline and people, please visit
www.kymeratx.com or follow us on X (formerly Twitter) or
LinkedIn.
Investor Contact: Justine
Koenigsberg Vice President, Investor
Relations investors@kymeratx.com 857-285-5300 |
Media Contact: Todd
Cooper Senior Vice President, Corporate
Affairs media@kymeratx.com 857-285-5300 |
Kymera Therapeutics (NASDAQ:KYMR)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Kymera Therapeutics (NASDAQ:KYMR)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024